Showing results (11-20 of 84) with videos related to
Sort By:
Pageof 9
The Journal of Antimicrobial Chemotherapy|April 15, 2021
Cell culture selections reveal favourable drug resistance profiles for doravirine and islatravirBluma G Brenner, Maureen Oliveira, Ruxandra-Ilinca Ibanescu, et al.The Journal of Antimicrobial Chemotherapy|July 14, 2011
Transmission dynamics of the M184V drug resistance mutation in primary HIV infectionMark A Wainberg, Daniela Moisi, Maureen Oliveira, et al.Antimicrobial Agents and Chemotherapy|June 19, 2002
Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1Karidia Diallo, Maureen Oliveira, Daniela Moisi, et al.The Journal of Antimicrobial Chemotherapy|June 12, 2023
Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressureBluma G Brenner, Maureen Oliveira, Ruxandra-Ilinca Ibanescu, et al.Retrovirology|October 9, 2010
Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype CHong-Tao Xu, Yudong Quan, Eugene Asahchop, et al.The Journal of Antimicrobial Chemotherapy|July 5, 2015
Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washoutNathan Osman, Thibault Mesplède, Peter K Quashie, et al.AIDS (London, England)|June 13, 2018
Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washoutNathan Osman, Thibault Mesplède, Maureen Oliveira, et al.Antimicrobial Agents and Chemotherapy|October 27, 2004
Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue cultureMarco Petrella, Maureen Oliveira, Daniela Moisi, et al.Antimicrobial Agents and Chemotherapy|February 19, 2009
Apricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutationsMaureen Oliveira, Daniela Moisi, Bonnie Spira, et al.Journal of the International AIDS Society|November 15, 2014
HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group MAgnès Depatureaux, Thibault Mesplède, Peter Quashie, et al.Pageof 9